The humoral and cellular response to mRNA SARS-CoV-2 vaccine is influenced by HLA polymorphisms.
HLA
SARS-CoV-2
cellular immunity
health care workers
mRNA vaccination
Journal
HLA
ISSN: 2059-2310
Titre abrégé: HLA
Pays: England
ID NLM: 101675570
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
01
02
2023
received:
23
11
2022
accepted:
20
03
2023
medline:
7
8
2023
pubmed:
4
4
2023
entrez:
3
4
2023
Statut:
ppublish
Résumé
Host genetic variability contributes to susceptibility to SARS-CoV-2 infection and COVID-19 evolution and the role of HLA system has not clearly emerged, suggesting the involvement of other factors. Studying response to vaccination with Spyke protein mRNA represents an ideal model to highlight whether the humoral or cellular responses are influenced by HLA. Four hundred and sixteen workers, vaccinated with Comirnaty beginning 2021, were selected within the Azienda Ospedaliera Universitaria "Città della Salute e della Scienza di Torino." The humoral response was determined with the LIAISON® kit, while the analysis of the cellular response was performed with the Quantiferon SARS-CoV-2 assay, for the S1 (receptor-binding domain; Ag1) and S1 and S2 (Ag2) subunits of the Spyke protein. Six HLA loci were typed by next-generation sequencing. Associations between HLA and vaccine response were performed with univariate and multivariate analyses. An association was found between A*03:01, B*40:02 and DPB1*06:01 and high antibody concentration and between A*24:02, B*08:01 and C*07:01 and low humoral responses. The haplotype HLA-A*01:01 ~ B1*08:01 ~ C*07:01 ~ DRB1*03:01 ~ DQB1*02:01 conferred an increased risk of low humoral response. Considering cellular responses, 50% of the vaccinated subjects responded against Ag1 and 59% against Ag2. Carriers of DRB1*15:01 displayed a higher cellular response both to Ag1 and Ag2 compared to the rest of the cohort. Similarly, DRB1*13:02 predisposed to a robust cellular response to Ag1 and Ag2, while DRB1*11:04 showed an opposite trend. Cellular and humoral responses to Comirnaty are influenced by HLA. Humoral response is mainly associated to class I alleles, with A*03:01, previously associated to protection against severe COVID-19, and response to vaccination, standing out. Cellular response predominantly involves class II alleles, with DRB1*15:01 and DPB1*13:01 prevailing. Affinity analysis for Spyke peptides is generally in line with the association results.
Substances chimiques
COVID-19 Vaccines
0
BNT162 Vaccine
0
HLA-DRB1 Chains
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
301-315Informations de copyright
© 2023 The Authors. HLA: Immune Response Genetics published by John Wiley & Sons Ltd.
Références
Gupta K, Kaur G, Pathak T, Banerjee I. Systematic review and meta-analysis of human genetic variants contributing to COVID-19 susceptibility and severity. Gene. 2022;844:146790.
van der Made CI, Netea MG, van der Veerdonk FL, Hoischen A. Clinical implications of host genetic variation and susceptibility to severe or critical COVID-19. Genome Med. 2022;14(1):96.
Zhang Q, Bastard P, Effort CHG, Cobat A, Casanova JL. Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature. 2022;603(7902):587-598.
Blackwell JM, Jamieson SE, Burgner D. HLA and infectious diseases. Clin Microbiol Rev. 2009;22(2):370-385.
Matzaraki V, Kumar V, Wijmenga C, Zhernakova A. The MHC locus and genetic susceptibility to autoimmune and infectious diseases. Genome Biol. 2017;18(1):76.
Baruah V, Bose S. Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV. J Med Virol. 2020;92(5):495-500.
Nguyen A, David JK, Maden SK, et al. Human leukocyte antigen susceptibility map for severe acute respiratory syndrome coronavirus 2. J Virol. 2020;94(13):e00510-20.
Cruz R, Almeida SD, Heredia ML, et al. Novel genes and sex differences in COVID-19 severity. Hum Mol Genet. 2022;31:3789-3806.
Namkoong H, Edahiro R, Takano T, et al. DOCK2 is involved in the host genetics and biology of severe COVID-19. Nature. 2022;609(7928):754-760.
Severe Covid-19 GWAS Group, Ellinghaus D, Degenhardt F, et al. Genomewide association study of severe covid-19 with respiratory failure. N Engl J Med. 2020;383(16):1522-1534.
Kousathanas A, Pairo-Castineira E, Rawlik K, et al. Whole-genome sequencing reveals host factors underlying critical COVID-19. Nature. 2022;607(7917):97-103.
Ben Shachar S, Barda N, Manor S, et al. MHC haplotyping of SARS-CoV-2 patients: HLA subtypes are not associated with the presence and severity of COVID-19 in the Israeli population. J Clin Immunol. 2021;41(6):1154-1161.
Augusto DG, Hollenbach JA. HLA variation and antigen presentation in COVID-19 and SARS-CoV-2 infection. Curr Opin Immunol. 2022;76:102178.
Deb P, Zannat KE, Talukder S, Bhuiyan AH, Jilani MSA, Saif-Ur-Rahman KM. Association of HLA gene polymorphism with susceptibility, severity, and mortality of COVID-19: a systematic review. HLA. 2022;99(4):281-312.
Amoroso A, Magistroni P, Vespasiano F, et al. HLA and AB0 polymorphisms may influence SARS-CoV-2 infection and COVID-19 severity. Transplantation. 2021;105(1):193-200.
Correale P, Mutti L, Pentimalli F, et al. HLA-B*44 and C*01 prevalence correlates with Covid19 spreading across Italy. Int J Mol Sci. 2020;21(15):5205-5217.
Guerini FR, Bolognesi E, Lax A, et al. HLA allele frequencies and association with severity of COVID-19 infection in northern Italian patients. Cell. 2022;11(11):1792-1800.
Novelli A, Andreani M, Biancolella M, et al. HLA allele frequencies and susceptibility to COVID-19 in a group of 99 Italian patients. HLA. 2020;96(5):610-614.
Pisanti S, Deelen J, Gallina AM, et al. Correlation of the two most frequent HLA haplotypes in the Italian population to the differential regional incidence of Covid-19. J Transl Med. 2020;18(1):352.
Littera R, Chessa L, Deidda S, et al. Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection. PLoS One. 2021;16(8):e0255608.
Upreti S, Samant M. A review on immunological responses to SARS-CoV-2 and various COVID-19 vaccine regimens. Pharm Res. 2022;39(9):2119-2134.
Kyriakidis NC, Lopez-Cortes A, Gonzalez EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines. 2021;6(1):28.
Grigoryan L, Pulendran B. The immunology of SARS-CoV-2 infections and vaccines. Semin Immunol. 2020;50:101422.
Costa C, Migliore E, Galassi C, et al. Factors influencing level and persistence of anti SARS-CoV-2 IgG after BNT162b2 vaccine: evidence from a large cohort of healthcare workers. Vaccines (Basel). 2022;10(3):474-484.
Scozzari G, Costa C, Migliore E, et al. Prevalence, persistence, and factors associated with SARS-CoV-2 IgG seropositivity in a large cohort of healthcare workers in a Tertiary Care University Hospital in Northern Italy. Viruses. 2021;13(6):1064-1075.
Costa C, Scozzari G, Migliore E, et al. Cellular immune response to BNT162b2 mRNA COVID-19 vaccine in a large cohort of healthcare workers in a Tertiary Care University Hospital. Vaccines (Basel). 2022;10(7):1031-1048.
Bonelli F, Blocki FA, Bunnell T, et al. Evaluation of the automated LIAISON((R)) SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies. Clin Chem Lab Med. 2021;59(8):1463-1467.
Standard WI. First WHO International Standard for Anti-SARS-CoV-2 Immunoglobulin (Human). Instructions for Use (Version 2.0). World Health Organization; 2020.
Jaganathan S, Stieber F, Rao SN, et al. Preliminary evaluation of QuantiFERON SARS-CoV-2 and QIAreach anti-SARS-CoV-2 total test in recently vaccinated individuals. Infect Dis Ther. 2021;10(4):2765-2776.
Robinson J, Barker DJ, Georgiou X, Cooper MA, Flicek P, Marsh SGE. IPD-IMGT/HLA Database. Nucleic Acids Res. 2020;48(D1):D948-D955.
Bui HH, Sidney J, Peters B, et al. Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics. 2005;57(5):304-314.
Reardon B, Kosaloglu-Yalcin Z, Paul S, Peters B, Sette A. Allele-specific thresholds of eluted ligands for T-cell epitope prediction. Mol Cell Proteomics. 2021;20:100122.
Paul S, Lindestam Arlehamn CS, Scriba TJ, et al. Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes. J Immunol Methods. 2015;422:28-34.
Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol. 1995;12(5):921-927.
Bishop YMMFS, Holland PW. Discrete multivariate analysis. Theory and Practice. MIT Press; 1975.
Rendine S, Ferrero NM, Sacchi N, Costa C, Pollichieni S, Amoroso A. Estimation of human leukocyte antigen class I and class II high-resolution allele and haplotype frequencies in the Italian population and comparison with other European populations. Hum Immunol. 2012;73(4):399-404.
Jahantigh HR, Stufano A, Lovreglio P, Rezaee SA, Ahmadi K. In silico identification of epitope-based vaccine candidates against HTLV-1. J Biomol Struct Dyn. 2022;40(15):6737-6754.
Moin AT, Patil RB, Tabassum T, et al. Immunoinformatics approach to design novel subunit vaccine against the Epstein-Barr virus. Microbiol Spectr. 2022;10(5):e0115122.
Mortier MC, Jongert E, Mettens P, Ruelle JL. Sequence conservation analysis and in silico human leukocyte antigen-peptide binding predictions for the Mtb72F and M72 tuberculosis candidate vaccine antigens. BMC Immunol. 2015;16:63.
Negahdaripour M, Nezafat N, Eslami M, et al. Structural vaccinology considerations for in silico designing of a multi-epitope vaccine. Infect Genet Evol. 2018;58:96-109.
Raza MT, Mizan S, Yasmin F, Akash AS, Shahik SM. Epitope-based universal vaccine for human T-lymphotropic virus-1 (HTLV-1). PLoS One. 2021;16(4):e0248001.
Sakib MS, Islam MR, Hasan AK, Nabi AH. Prediction of epitope-based peptides for the utility of vaccine development from fusion and glycoprotein of nipah virus using in silico approach. Adv Bioinformatics. 2014;2014:402492.
Yasmin T, Akter S, Debnath M, Ebihara A, Nakagawa T, Nabi AH. In silico proposition to predict cluster of B- and T-cell epitopes for the usefulness of vaccine design from invasive, virulent and membrane associated proteins of C. jejuni. Silico Pharmacol. 2016;4(1):5.
Southwood S, Sidney J, Kondo A, et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol. 1998;160(7):3363-3373.
Karnaukhov V, Paes W, Woodhouse IB, et al. HLA variants have different preferences to present proteins with specific molecular functions which are complemented in frequent haplotypes. Front Immunol. 2022;13:1067463.
Rasmussen M, Fenoy E, Harndahl M, et al. Pan-specific prediction of peptide-MHC class I complex stability, a correlate of T cell immunogenicity. J Immunol. 2016;197(4):1517-1524.
Khor SS, Omae Y, Takeuchi JS, et al. An association study of HLA with the kinetics of SARS-CoV-2 spike specific IgG antibody responses to BNT162b2 mRNA vaccine. Vaccines (Basel). 2022;10(4):68-77.
Gutierrez-Bautista JF, Sampedro A, Gomez-Vicente E, et al. HLA class II polymorphism and humoral immunity induced by the SARS-CoV-2 mRNA-1273 vaccine. Vaccines (Basel). 2022;10(3):183-191.
Astbury S, Reynolds CJ, Butler DK, et al. HLA-DR polymorphism in SARS-CoV-2 infection and susceptibility to symptomatic COVID-19. Immunology. 2022;166(1):68-77.
Crocchiolo R, Gallina AM, Pani A, et al. Polymorphism of the HLA system and weak antibody response to BNT162b2 mRNA vaccine. HLA. 2022;99(3):183-191.
Mentzer AJ, O'Connor D, Bibi S, et al. Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection. Nat Med. 2022;33(1):e2378.
Ishak A, Mehendale M, AlRawashdeh MM, et al. The association of COVID-19 severity and susceptibility and genetic risk factors: a systematic review of the literature. Gene. 2022;836:146674.
Dobrijevic Z, Gligorijevic N, Sunderic M, et al. The association of human leucocyte antigen (HLA) alleles with COVID-19 severity: a systematic review and meta-analysis. Rev Med Virol. 2022;33:e2378.
Maruthamuthu S, Rajalingam K, Kaur N, et al. Individualized constellation of killer cell immunoglobulin-like receptors and cognate HLA class I ligands that controls natural killer cell antiviral immunity predisposes COVID-19. Front Genet. 2022;13:845474.
Bolze A, Neveux I, Schiabor Barrett KM, et al. HLA-A *03:01 is associated with increased risk of fever, chills, and stronger side effects from Pfizer-BioNTech COVID-19 vaccination. HGG Adv. 2022;3(2):100084.
Sahin U, Muik A, Vogler I, et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. 2021;595(7868):572-577.